1227 related articles for article (PubMed ID: 22182688)
1. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
[TBL] [Abstract][Full Text] [Related]
2. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
[TBL] [Abstract][Full Text] [Related]
3. Depressive-like phenotype induced by AAV-mediated overexpression of human α-synuclein in midbrain dopaminergic neurons.
Caudal D; Alvarsson A; Björklund A; Svenningsson P
Exp Neurol; 2015 Nov; 273():243-52. PubMed ID: 26363495
[TBL] [Abstract][Full Text] [Related]
4. Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity.
Gaugler MN; Genc O; Bobela W; Mohanna S; Ardah MT; El-Agnaf OM; Cantoni M; Bensadoun JC; Schneggenburger R; Knott GW; Aebischer P; Schneider BL
Acta Neuropathol; 2012 May; 123(5):653-69. PubMed ID: 22361813
[TBL] [Abstract][Full Text] [Related]
5. Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease.
Ulusoy A; Decressac M; Kirik D; Björklund A
Prog Brain Res; 2010; 184():89-111. PubMed ID: 20887871
[TBL] [Abstract][Full Text] [Related]
6. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
[TBL] [Abstract][Full Text] [Related]
7. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
8. Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease.
Dusonchet J; Bensadoun JC; Schneider BL; Aebischer P
Neurobiol Dis; 2009 Jul; 35(1):32-41. PubMed ID: 19348945
[TBL] [Abstract][Full Text] [Related]
9. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
Coune PG; Bensadoun JC; Aebischer P; Schneider BL
J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
[TBL] [Abstract][Full Text] [Related]
10. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
Maingay M; Romero-Ramos M; Carta M; Kirik D
Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
[TBL] [Abstract][Full Text] [Related]
11. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.
Eslamboli A; Romero-Ramos M; Burger C; Bjorklund T; Muzyczka N; Mandel RJ; Baker H; Ridley RM; Kirik D
Brain; 2007 Mar; 130(Pt 3):799-815. PubMed ID: 17303591
[TBL] [Abstract][Full Text] [Related]
12. Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons.
Ulusoy A; Björklund T; Buck K; Kirik D
Neurobiol Dis; 2012 Sep; 47(3):367-77. PubMed ID: 22659302
[TBL] [Abstract][Full Text] [Related]
13. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
15. Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration.
Xilouri M; Brekk OR; Landeck N; Pitychoutis PM; Papasilekas T; Papadopoulou-Daifoti Z; Kirik D; Stefanis L
Brain; 2013 Jul; 136(Pt 7):2130-46. PubMed ID: 23757764
[TBL] [Abstract][Full Text] [Related]
16. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
[TBL] [Abstract][Full Text] [Related]
17. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
[TBL] [Abstract][Full Text] [Related]
18. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
Chu Y; Kordower JH
Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
[TBL] [Abstract][Full Text] [Related]
19. Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein.
Park SS; Schulz EM; Lee D
Eur J Neurosci; 2007 Dec; 26(11):3104-12. PubMed ID: 18005066
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.
Decressac M; Mattsson B; Björklund A
Exp Neurol; 2012 May; 235(1):306-15. PubMed ID: 22394547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
